News
Trump administration says it is trying to prevent war but raises eyebrows by calling for commitments from Australia and Japan ...
ImmunityBio’s ANKTIVA shows promise, but modest growth, high cash burn, and rising competition raise red flags. Read why IBRX stock is a sell.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback